These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 32973552)
1. The NLRP3 Inflammasome: Role and Therapeutic Potential in Pain Treatment. Starobova H; Nadar EI; Vetter I Front Physiol; 2020; 11():1016. PubMed ID: 32973552 [TBL] [Abstract][Full Text] [Related]
2. The NLRP3 inflammasome: a potential therapeutic target for traumatic brain injury. Ismael S; Ahmed HA; Adris T; Parveen K; Thakor P; Ishrat T Neural Regen Res; 2021 Jan; 16(1):49-57. PubMed ID: 32788447 [TBL] [Abstract][Full Text] [Related]
3. Role of NLRP3 inflammasome in inflammatory bowel diseases. Tourkochristou E; Aggeletopoulou I; Konstantakis C; Triantos C World J Gastroenterol; 2019 Sep; 25(33):4796-4804. PubMed ID: 31543674 [TBL] [Abstract][Full Text] [Related]
4. The selective Nlrp3 inflammasome inhibitor Mcc950 attenuates lung ischemia-reperfusion injury. Xu KY; Wu CY; Tong S; Xiong P; Wang SH Biochem Biophys Res Commun; 2018 Sep; 503(4):3031-3037. PubMed ID: 30146255 [TBL] [Abstract][Full Text] [Related]
5. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Guo C; Fu R; Wang S; Huang Y; Li X; Zhou M; Zhao J; Yang N Clin Exp Immunol; 2018 Nov; 194(2):231-243. PubMed ID: 30277570 [TBL] [Abstract][Full Text] [Related]
6. Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression. Liu HJ; Pan XX; Liu BQ; Gui X; Hu L; Jiang CY; Han Y; Fan YX; Tang YL; Liu WT J Neuroinflammation; 2017 Apr; 14(1):74. PubMed ID: 28376889 [TBL] [Abstract][Full Text] [Related]
7. The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. Szekanecz Z; Szamosi S; Kovács GE; Kocsis E; Benkő S Arch Biochem Biophys; 2019 Jul; 670():82-93. PubMed ID: 30710503 [TBL] [Abstract][Full Text] [Related]
8. Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer. Missiroli S; Perrone M; Boncompagni C; Borghi C; Campagnaro A; Marchetti F; Anania G; Greco P; Fiorica F; Pinton P; Giorgi C Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064909 [TBL] [Abstract][Full Text] [Related]
9. Migraine and neuroinflammation: the inflammasome perspective. Kursun O; Yemisci M; van den Maagdenberg AMJM; Karatas H J Headache Pain; 2021 Jun; 22(1):55. PubMed ID: 34112082 [TBL] [Abstract][Full Text] [Related]
10. Non-canonical Inflammasome-Mediated IL-1β Production by Primary Endometrial Epithelial and Stromal Fibroblast Cells Is NLRP3 and Caspase-4 Dependent. Kelly P; Meade KG; O'Farrelly C Front Immunol; 2019; 10():102. PubMed ID: 30804935 [TBL] [Abstract][Full Text] [Related]
11. NLRP3 inflammasome activation in D-galactosamine and lipopolysaccharide-induced acute liver failure: role of heme oxygenase-1. Kim SJ; Lee SM Free Radic Biol Med; 2013 Dec; 65():997-1004. PubMed ID: 23994575 [TBL] [Abstract][Full Text] [Related]
12. The RNA- and TRIM25-Binding Domains of Influenza Virus NS1 Protein Are Essential for Suppression of NLRP3 Inflammasome-Mediated Interleukin-1β Secretion. Moriyama M; Chen IY; Kawaguchi A; Koshiba T; Nagata K; Takeyama H; Hasegawa H; Ichinohe T J Virol; 2016 Apr; 90(8):4105-4114. PubMed ID: 26865721 [TBL] [Abstract][Full Text] [Related]
13. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production. Yu X; Lan P; Hou X; Han Q; Lu N; Li T; Jiao C; Zhang J; Zhang C; Tian Z J Hepatol; 2017 Apr; 66(4):693-702. PubMed ID: 28027970 [TBL] [Abstract][Full Text] [Related]
14. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Elliott EI; Sutterwala FS Immunol Rev; 2015 May; 265(1):35-52. PubMed ID: 25879282 [TBL] [Abstract][Full Text] [Related]
15. NOD-Like Receptor Protein 3 Inflammasome-Dependent IL-1β Accelerated ConA-Induced Hepatitis. Luan J; Zhang X; Wang S; Li Y; Fan J; Chen W; Zai W; Wang S; Wang Y; Chen M; Meng G; Ju D Front Immunol; 2018; 9():758. PubMed ID: 29692782 [TBL] [Abstract][Full Text] [Related]
16. Negative regulators and their mechanisms in NLRP3 inflammasome activation and signaling. Kim JK; Jin HS; Suh HW; Jo EK Immunol Cell Biol; 2017 Aug; 95(7):584-592. PubMed ID: 28356568 [TBL] [Abstract][Full Text] [Related]
17. A Novel Sex-Dependent Target for the Treatment of Postoperative Pain: The NLRP3 Inflammasome. Cowie AM; Dittel BN; Stucky CL Front Neurol; 2019; 10():622. PubMed ID: 31244767 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases. Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768 [TBL] [Abstract][Full Text] [Related]
19. Inflammasome Activation in Chronic Glomerular Diseases. Conley SM; Abais JM; Boini KM; Li PL Curr Drug Targets; 2017; 18(9):1019-1029. PubMed ID: 27538510 [TBL] [Abstract][Full Text] [Related]
20. Targeting the NOD-, LRR- and Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome in Psoriasis and Fatigue. Seguro CK; Demory Beckler M; Kesselman MM Cureus; 2022 May; 14(5):e24704. PubMed ID: 35663672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]